Shares in Telix Pharmaceuticals Ltd (ASX: TLX) will be on watch this morning after the company late yesterday revealed it had met its full year revenue guidance and had grown its fourth quarter revenue strongly.
The drug developer said its full year revenue had come in at US$804 million ($1.2 billion), in line with the company's upgraded guidance of US$800-US$820 million.
Image source: Getty Images
Numbers strong across the board
Telix's revenue for the fourth quarter came in at US$208 million, up 46% comparted with the same quarter last year.
Telix said its precision medicine division had revenue of about US$161 million, up 4% on the third quarter's result, "driven by the successful United States launch of Gozellix following reimbursement by Centers for Medicare and Medicaid Services (CMS), effective from 1 October 2025''.
The company's managing director Dr Christian Behrenbruch said it was a good result.
Telix's Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful U.S. launch of Gozellix. This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing. With strong early uptake of Gozellix and a robust pipeline of key accounts integrating Gozellix and ARTMS technology, Telix is well positioned for sustained growth in 2026.
Trials progressing
On the clinical trial front the company said the first international patients had been dosed in part 2 of the ProstACT Global Phase 3 study of TLX591-Tx in advanced prostate cancer.
This compound is the company's lead prostate cancer therapy candidate, and the company is also preparing for a readout of safety and dosimetry data from Part 1 of the trial.
Telix said further:
The study is open for enrolment in Australia, New Zealand and Canada, with further sites to be opened in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan9, where regulatory approvals have already been granted. Data from Part 1 will be presented to the U.S. Food and Drug Administration (FDA) to ascertain eligibility for U.S. patients to participate in Part 2.
The company said it had also dosed the first US patinets in Solace, which was a study of its therapeutic candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers.
Telix also yesterday announced that China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted a new drug application (NDA) for Illuccix, which is Telix's lead prostate cancer imaging agent.
The company said further:
The NDA was submitted with Telix's strategic partner for the Greater China region, Grand Pharmaceutical Group Limited. Seeking a broad label that reflects clinical utility at multiple stages of prostate cancer care, the submission includes data from the Illuccix China Pivotal Phase 3 Registration study1, which reported positive top-line results in December 2025.
Telix said more than 134,000 men were diagnosed with prostate cancer in 2022, with that number increasing by about 6% each year.
Illuccix has already been approved by the US Food and Drug Administration, Australia's Therapeutic Goods Administration, by the United Kingdom Medicines and Healthcare Products Regulatory Agency and in 19 countries within the European Economic Area.
